Peptide parathyroid hormone analogs

Details Peptide parathyroid hormone analogs Peptide parathyroid hormone analogs

1999-01-12

2002-10-29

Davenport, Avis M. (Department: 1654)

Chemistry: natural resins or derivatives; peptides or proteins;

Peptides of 3 to 100 amino acid residues

Cyclic peptides

C514S009100, C514S011400

Reexamination Certificate

active

06472505

ABSTRACT:

TECHNICAL FIELD
This invention is directed to compounds and their preparation, to pharmaceutical compositions containing the compounds and to their use in the treatment of physiological conditions capable of being modulated by agonist or antagonist activity on parathyroid hormone receptors. More particularly, this invention is directed to peptide parathyroid hormone analogs and peptide parathyroid hormone related protein analogs.
BACKGROUND OF THE INVENTION
Human parathyroid hormone (hPTH) is an 84 amino acid protein which is a major regulator of calcium homeostasis. Parathyroid hormone-related protein (hPTHrP) is a 139 to 171 amino acid protein with N-terminal homology to hPTH. The N-terminal fragments of hPTH and hPTHrP, particularly those consisting of amino acids 1-34, retain the full biological activity of the parent hormone.
hPTH(1-34) has the following amino acid sequence:
Ser-Val-Ser-Glu-Ile-Gln-Leu-Met-His-Asn-Leu-Gly-Lys-His-Leu-Asn-Ser-Met-
Glu-Arg-Val-Glu-Trp-Leu-Arg-Lys-Lys-Leu-Gln-Asp-Val-His-Asn-Phe. (SEQ ID NO: 1)
hPTHrP has the following amino acid sequence:
Ala-Val-Ser-Glu-His-Gln-Leu-Leu-His-Aso-Lys-Gly-Lys-Ser-Ile-(Gln-Aso-Leu-
Arg-Arg-Arg-Phe-Phe-Leu-His-His-Leu-Ile-Ala-Glu-Ile-His-Thr-Ala. (SEQ ID NO: 2)
The biological activity of hPTH is reflected in the activation of two secondary messenger systems: G-protein coupled adenylyl cyclase (AC) and G-protein coupled and uncoupled protein kinase C (PKC) activity. The N-terminal fragments hPTH(1-34)OH and hPTH(1-31)NH2 have been demonstrated to be anabolic with respect to bone formation in humans and ovariectomized rats, respectively. This increase in bone growth has been demonstrated to be coupled with stimulation of adenylyl cyclase activity. Analogs of these N-terminal fragments have significant therapeutic potential for the treatment of physiological conditions associated with bone cell calcium regulation including hypocalcemia; osteoporosis; osteopenia; and disorders associated with osteoporosis and osteopenia such as hyperparathyroidism, hypoparathyroidism, and Cushings syndrome; glucocorticoid- and immunosuppressant-induced osteopaenia; and bone fracture and bone refracture repair.
It has also been established that deletion of up to six amino acid residues from the N-terminus of hPTH(1-34) markedly decreases the resulting analog's ability to stimulate adenylyl cyclase while having little effect on receptor binding. Thus, analogs of hPTH(1-34) truncated by up to six amino acid residues at the N-teminus inhibit the action of PTH and are useful in the treatment of disorders characterized by an excess of PTH such as hyperparathyrodism and hyperparathyrodism-related hypercalcemia crisis, hypercalcemia of malignancy, renal failure and hypertension.
Acyclic analogs of hPTH(1-27) to (1-34) are disclosed in U.S. Pat. No. 4,086,196. Acyclic analogs of hPTH(1-34) and hPTHrP (1-34) are disclosed in U.S. Pat. No. 5,589,452. [Nle
8
, Nle
18
, Tyr
34
, or Phe
34
]hPTH(1-34) are disclosed in U.S. Pat. No. 4,656,250. [Nle
8
, Nle
18
, Tyr
34
]hPTH(1-34) and N-truncated derivatives thereof are disclosed in U.S. Pat. Nos. 4,771,124 and 4,423,037. Other acyclic analogs of PTH(1-34) are disclosed in U.S. Pat. Nos. 5,723,577 and 5,434,246, WO 97/02834, EPA 561 412-A1, EPA 748,817-A2, WO-94/02510, WO9603437, and WO951 1988-A 1. Analogs of hPTH(1-28)NH
2
to hPTH(1-31)NH
2
and [Leu
27
]hPTH(1-28)NH
2
to [Leu
27
]hPTH(1-33)NH
2
are decribed in U.S. Pat. No. 5,556,940. Acyclic antagonists of the PTH receptor including N-terminally-truncated analogs of PTH are disclosed in U.S. Pat. Nos. 5,446,130, 5,229,489, 4,771,124 and 4,423,037.
Cyclic and bicyclic analogs of hPTH and hPTHrP have been disclosed. Cyclo(Lys
26
-Asp
30
)[Leu
27
]hPTH(1-34)NH
2
and cyclo(Lys
27
-Asp
30
)hPTH(1-34)NH
2
are disclosed in U.S. Pat. No. 5,556,940. Cyclo(Lys
26
-Asp
30
)[Leu
27
]hPTH(1-31)NH
2
, cyclo(Glu
22
-Lys
26
)[Leu
27
]hPTH(1-31)NH
2
, and cyclo(Lys
27
-Asp
30
)hPTH(1-31)NH
2
are decribed by Barbier, et al.,
J. Med. Chem
. 1997, 40, 1373. Monocyclic and bicyclic derivatives of hPTH(1-34) or hPTHrP(1-34) are disclosed in patent documents WO 96/40193. DE19508672-A1, and by A. Bisello. et al., in
Biochemistry
1997, 36, 3293. Cyclo(Lys
13
-Asp
17
)hPTHrP(7-34)NH
2
, a potent antagonist of the PTH rcceptor, is disclosed by M. Chorev, et al.,
Biochemistry
1991, 30, 5698. Also, Kanmera, et al., has described a series of amide-containing analogs of hPTHrP,
Peptide Chemistry
1993: Okada, Y., ed.; Protein Research Foundation, Osaka, 1994, 321-324.”
SUMMARY OF THE INVENTION
This invention is directed to a cyclic peptide compound of formula I
X—A
10
—A
11
—A
12
—A
13
—A
14
—A
15
—A
16
—A
17
—A
18
—A
19
—A
20
—A
21
—A
22
—A
23
—A
24
—A
25
—A
26
—A
27
—Y  I
or a pharmaceutically acceptable salt or prodrug thereof wherein
X is selected from the group consisting of
(a) R
1a
—A
0
—A
1
—A
2
—A
3
—A
4
—A
5
—A
6
—A
7
—A
8
—A
9
—,
(b) R
1a
—A
2
—A
3
—A
4
—A
5
—A
6
—A
7
—A
8
—A
9
—,
(c) R
1b
—A
3
—A
4
—A
5
—A
6
—A
7
—A
8
—A
9
—,
(d) R
1a
—A
4
—A
5
—A
6
—A
7
—A
8
—A
9
—,
(e) R
1a
—A
5
—A
6
—A
7
—A
8
—A
9
—,
(f) R
1a
—A
6
—A
7
—A
8
—A
9
—,
(g) R
1a
—A
7
—A
8
—A
9
—,
(h) R
1a
—A
8
—A
9
—,
(i) R
1a
—A
9
—, and
(j) R
1a
—;
Y is selected from the group consisting of
(a) —R
3
,
(b) —A
28
—R
3
,
(c) —A
28
—A
29
—R
3
,
(d) —A
28
—A
29
—A
30
—R
3
,
(e) —A
28
—A
29
—A
30
—A
31
—R
3
,
(f) —A
28
—A
29
—A
30
—A
31
—A
32
—R
3
,
(g) —A
28
—A
29
—A
30
—A
31
—A
32
—A
33
—R
3
, and
(h) —A
28
—A
29
—A
30
—A
31
—A
32
—A
33
—A
34
—R
3
;
R
1a
is H, alkyl, aralkyl or —COR
2
;
R
1b
is R
1a
or a group of formula
R
2
is alkyl, alkenyl, alkynyl, aryl or aralkyl;
R
3
is a group of formula A
35
—OR
4
or A
35
—NR
4
R
5
;
R
4
and R
5
are independently H or lower alkyl;
R
6
and R
9
are independently H or alkyl;
R
7
is alkyl;
R
8
is H, alkyl or COR
2
;
R
10
is H or halogen;
R
11
is alkyl or aralkyl;
m is 1, 2 or 3;
n is 3 or 4;
A
0
is absent or a peptide of from one to six amino acid residues;
A
1
is Ser, Ala, Gly or D-Pro, or an equivalent amino acid thereof;
A
2
is Ala, Val or Gly, or an equivalent amino acid thereof;
A
3
is Ala, Ser, Gly or D-Pro, or an equivalent amino acid thereof;
A
4
is Glu, Ala or Gly, or an equivalent amino acid thereof;
A
5
is Ile, His, Ala or Gly, or an equivalent amino acid thereof;
A
6
is Ala, Gln, Gly or D-Pro, or an equivalent amino acid thereof;
A
7
is Ala, Leu, Gly, or an equivalent amino acid thereof;
A
8
is Leu, Nle, Gly or D-Pro, or an equivalent amino acid thereof;
A
9
is His, Ala, D-Pro or Gly, or an equivalent amino acid thereof;
A
10
is Ala, Asn, Asp, Cys, homo-Cys, Glu, Gly, Lys, Orn, Ser, Thr, D-Pro, —NHCH(CH
2
)
m
NH
2
)CO— or —NHCH[(CH
2
)
n
CO
2
H]CO—;
A
11
is Ala, Gly, Leu or Lys, or an equivalent amino acid thereof;
A
12
is Ala or Gly, or an equivalent amino acid thereof;
A
13
is Ala, Asn, Asp, Cys, homo-Cys, Glu, Gly, Lys, Orn, Ser, Thr, —NHCH(CH
2
)
m
NH
2
)CO— or —NHCH[(CH
2
)
n
CO
2
H]CO—;
A
14
is Ala, Asn, Asp, Cys, homo-Cys, Glu, Gly, His, Lys, Orn, Ser, Thr, D-Pro, —NHCH(CH
2
)
m
NH
2
)CO— or —NHCH[(CH
2
)
n
CO
2
H]CO—;
A
15
is Ala, Gly, Ile, D-Pro or Leu, or an equivalent amino acid thereof;
A
16
is Asn, Ala, Gly, D-Pro or Gln, or an equivalent amino acid thereof;
A
17
is Ala, Asn, Asp, Cys, homo-Cys, Glu, Gly, Lys, Orn, Ser, Thr, D-Pro, —NHCH(CH
2
)
m
NH
2
)CO— or —NHCH[(CH
2
)
n
CO
2
H]CO—;
A
18
is Asp, Cys, homo-Cys, Glu, His, Leu, Lys, Or, Nle, Ser, Thr, —NHCH(CH
2
)
m
NH
2
)CO— or —NHCH[(CH
2
)
n
CO
2
H]CO—;
A
19
is Arg or Glu, or an equivalent amino acid thereof;
A
20
is Arg or an equivalent amino acid thereof;
A
21
is Arg, Asp, Cys, homo-Cys, Glu, Lys, Orn, Ser, Thr, Val, —NHCH(CH
2
)
m
NH
2
)CO— or —NHCH[(CH
2
)
n
CO
2
H]CO—;
A
22
is Asp, Cys, homo-Cys, Glu, His, Lys, Orn, Phe, Ser, Thr, —NHCH(CH
2
)
m
NH
2
)CO— or —NHCH[(CH
2
)
n
CO
2
H]CO—;
A
23
is Leu, Phe or Trp, or an equivalent amino acid thereof;
A
24
is Leu or an equivalent

Affiliated with

Also associated with

Rating

Peptide parathyroid hormone analogs does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Peptide parathyroid hormone analogs, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Peptide parathyroid hormone analogs will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2999104